On May 25th, 2023, Insilico announced that the U.S. Food and Drug Administration (FDA) recently approved the initial investigational new drug (IND) application for ISM3091, a USP1 inhibitor for the treatment of patients with solid tumors. This is Insilico's first oncology program to advance to the clinical validation stage.
The open-label, multicenter Phase I clinical trial of ISM3091 will be conducted simultaneously in the U.S. and China to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors through dose escalation. Insilico has filed the IND submission to the U.S. FDA and the NMPA and expects to initiate the study in the U.S. center in July 2023.
Disclaimer
Investment Involves risk. Past performance does not represent future performance. Investor should read the product’s Prospectus for details and risk factors before making investment decision. The contents of this website is prepared and maintained by Mirae Asset Capital (China) Limited. This material has not been reviewed by the Securities and Futures Commission. Certain information contained in this website is compiled from third party sources. Whilst we have, to the best of its endeavor, ensured that such, information is accurate, complete and up-to-date, and has taken care in accurately reproducing the information. We accepts no liability for, any loss or damage of any kind resulting out of the unauthorized use of this website.
Apr 02, 2025
